David S. Salomon, Ph.D.

David S. Salomon, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Mouse Cancer Genetics Program


The embryonic cell surface signaling protein, Cripto-1, is re-expressed at a high frequency in a number of different cancers, including non-small cell lung carcinomas (NSLC). Dr. Salomon helped to develop a toxin-conjugated humanized monoclonal antibody (Mab) against Cripto-1 as an initial step in developing a targeted therapeutic for NSLC patients. This Mab (BIIB015) was then evaluated for therapeutic efficacy in a Phase II clinical trial. Dr. Salomon was involved in the initial discovery of the mouse and human Cripto-1 genes and in the characterization of the biological activities associated with this family of proteins that function as co-receptors and chaperones for different embryonic signaling pathways such as Nodal, Wnt and Notch, which are essential in the generation and maintenance of embryonic and cancer stem cells.

Areas of Expertise

Breast Cancer
Cell Signaling
Stem Cells
Mammary Gland Development
Embryonic Development
Small Molecule Inhibitors